Brinavess Articles
Merck & Co returns vernakalant rights to Cardiome
27 September 2012
Merck & Co drops development of oral vernakalant
20 March 2012
European approval for Merck & Co/Cardiome’s IV Brinavess; added use for AstraZeneca’s Seroquel recommended
2 September 2010
Batch of positive opinions from Europe's Committee for Medicinal Products for Human Use recent meetings
28 June 2010
Showing 1-5 of 5 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
